MELVILLE, N.Y.--(BUSINESS WIRE)--May 8, 2006--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP - News) announced today its financial results for the Company’s first quarter ended March 31, 2006. The Company reported total revenues of $116.4 million for the first quarter of 2006, an increase of $97.4 million (or over 500%) compared to revenues of $19.1 million for the first quarter of 2005. The increase is primarily due to the growth in revenues arising from worldwide Tarceva® (erlotinib) sales, and Macugen® (pegaptanib sodium injection)-related revenue streams. Total worldwide net sales of Tarceva for the first quarter of 2006 were $133 million. Total U.S. Macugen sales were $51 million for the first quarter of 2006.
